| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 7.07 | 0.08 (+1.14%) | 6.65 - 10.63 | 76.5 thousand (Above Avg) |
Market data as of 4:00PM 06/17/13. Quotes are delayed by at least 15 min.
| Open | 7.01 |
|---|---|
| Previous Close | 6.99 |
| Day's Range | 6.99 - 7.19 |
| Market Cap | 188.3M |
| Avg Volume (10 Day) | 43.5K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -260.23 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
No news headlines available for DRTX
| DRTX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.63 | |
| LT Debt/Equity | 0.63 | |
| Earnings Yield | -- | |
| Price/Sales | -- |
| Company | Last | Change |
|---|---|---|
| Galena Biopharma Inc | 2.11 | -2.76% |
| Neptune Technologies & Bioressources Inc | 3.00 | -0.33% |
| Corcept Therapeutics Inc | 1.81 | +0.56% |
| Acasti Pharma Inc | 2.70 | +1.89% |
| Cempra Inc | 7.12 | +1.71% |
Data is delayed by at least 15 min.